Leave of Morris Manning’s IP team for an alternative legal services firm
Alternative legal services firm Rimon Law has bolstered its intellectual property offering in Washington, DC, with the arrival of a team of pharmaceutical and biotechnology intellectual property attorneys from Morris, Manning & Martin.
Ping Wang, Michael Ye and John Murray joined the firm on November 1 as partners for intellectual property and patent prosecution.
In a statement announcing the team’s arrival, Rimon CEO and founding partner Michael Moradzadeh said the three lawyers had “exceptional” experience in the United States and China, as well as in “prominent” industries. “such as the pharmacy.
Rimon has experienced rapid growth this year. Earlier this month, he announced a merger with nine-lawyer firm Ibarra Abogados, based in Colombia, where Rimon began offering services in 2020.
In September, it opened its second German office and in July an office in Seoul. Over the past 10 months, it has also added offices in Montreal, Casablanca, Morocco and Paris, and currently operates from 45 locations across five continents.
Wang, originally a physician, began his legal career at Oblon, McClelland, Maier & Neustad and DLA Piper. In Washington, Wang’s practice covers all aspects of intellectual property, including patent prosecution, inter partes review, post-grand review, interference practice, advice and opinions regarding patentability, patent invalidity, freedom to operate and infringement, as well as due diligence in mergers and acquisitions in the biotechnology industry.
Wang said she was drawn to Rimon because of her entrepreneurial spirit and the “ownership” and “flexibility” she gives her attorneys in their practice. Wang also believes the alternative legal services firm offers the best way to serve clients in multiple jurisdictions, at a lower cost, with low overhead and “no internal bureaucracy.”
“We don’t need to delve into the administrative aspects of running a legal business,” Wang said. “We can focus on serving our customers.
Ye represents clients in patent litigation, opinion work, due diligence and licensing, as well as trademark and copyright litigation and licensing, and manages negotiations and transactions incoming and outgoing in China.
Murray represents clients in complex patent litigation, life sciences lawsuits and opinions, and due diligence, leading prosecutions both domestically and internationally. He has represented clients in a variety of industries, including startups and academics, biotechnology, chemical/organic chemistry, medical devices, molecular biology and pharmaceuticals, and his work includes patent infringement litigation, Hatch-Waxman and ITC 337 litigation.
Morris Manning did not return requests for comment at the time of publication.